Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cassava Sciences, Inc. - Common Stock (NQ:SAVA)

2.120 -0.040 (-1.86%)
Streaming Delayed Price Updated: 12:31 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cassava Sciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’s Disease
From Cassava Sciences, Inc.
Via GlobeNewswire
MRI Data Suggest Simufilam is Not Associated with Amyloid-related Imaging Abnormalities (ARIA)
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Inc. (NASDAQ: SAVA) Leading the Way in Tuesday Trading Based on Percentage Gain
Via Investor Brand Network
Statement by Cassava Sciences Regarding an Internal CUNY Report Leaked to the Press
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences to Present at the Jefferies Biotech CNS/Neuro Summit in NY
CEO to Present on Wednesday, October 11th, at 10:30am ET 
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer’s Disease
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Announces Positive Interim Safety Review of Simufilam On-going Phase 3 Trials in Patients with Alzheimer’s Disease
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimer’s Disease
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Invited to Present in Four Upcoming Investor Conferences
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Reports Q2 2023 Financial Results and Operating Updates
From Cassava Sciences, Inc.
Via GlobeNewswire
Oral Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial of Mild-to-Moderate Alzheimer’s Disease
From Cassava Sciences, Inc.
Via GlobeNewswire
New Research Shows Simufilam Suppresses Overactive mTOR
From Cassava Sciences, Inc.
Via GlobeNewswire
New Publication Highlights Basic Science Supporting Simufilam
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences to Present at the Jefferies Global Healthcare Conference
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Completes Patient Dosing in a Randomized Controlled Trial of Simufilam in Alzheimer’s Disease
From Cassava Sciences, Inc.
Via GlobeNewswire
New Data by Academic Researchers Highlights Biological Activity of Simufilam on Filamin A
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Reports Q1 2023 Financial Results and Operating Updates
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences to Present at the 2023 H.C. Wainwright Investor Conference
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Reports Full-year 2022 Financial Results and Operating Updates
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Stock Undervalued with Its $124 Price Target?
Casava Sciences Inc (NASDAQ: SAVA) stock has been the topic of much controversy in its quest for FDA approval for its simufilam drug. The Company is a 
Via MarketBeat
Cassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Mourns the Death of Board Member and Officer Nadav Friedmann, PhD, MD
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Announces Completion of Dosing in Open-label Study of Simufilam for Alzheimer’s Disease
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Announces Closing of $50 Million Registered Direct Offering
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock
From Cassava Sciences, Inc.
Via GlobeNewswire
CASSAVA SCIENCES INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Cassava Sciences, Inc. - SAVA
From Kahn Swick & Foti, LLC
Via Business Wire
Cassava Sciences Reports Third Quarter Financial Results for 2022 and Business Updates
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Files Lawsuit Against Perpetrators of “Short and Distort” Campaign
From Cassava Sciences, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.